Diabetic Cardiomyopathy represents a distinct form of cardiac dysfunction occurring in patients with diabetes, independent of hypertension, coronary artery disease, or valvular abnormalities. This session explores its molecular basis, diagnostic challenges, clinical implications, and evidence-based management strategies. As the global prevalence of diabetes rises, professionals increasingly search for a focused cardiology conference to understand the early detection and treatment of this progressive condition.

The description emphasizes that diabetic cardiomyopathy involves metabolic dysregulation, myocardial fibrosis, microvascular dysfunction, impaired calcium handling, and autonomic imbalance. Participants will learn how hyperglycemia, lipotoxicity, oxidative stress, and chronic inflammation progressively alter myocardial structure and function. The session explains how diastolic dysfunction develops early, followed by systolic impairment in more advanced stages.

Participants will review tools for diagnosing diabetic cardiomyopathy, including echocardiography, strain imaging, CMR T1/T2 mapping, biomarker analysis, and exercise testing. The session highlights challenges in differentiating diabetic cardiomyopathy from other causes of HFpEF and cardiomyopathy. Early signs—such as reduced global longitudinal strain—are emphasized to facilitate timely intervention.

A major emphasis is placed on implementing advanced diabetic cardiomyopathy management strategies. This includes optimal glucose control, cardioprotective antihyperglycemics (particularly SGLT2 inhibitors and GLP-1 receptor agonists), RAAS blockade, mineralocorticoid receptor antagonists, lifestyle changes, weight management, and exercise-based therapies. Participants explore how managing insulin resistance, obesity, and metabolic syndrome improves cardiac function.

The content also addresses high-risk populations—women, older adults, and individuals with longstanding diabetes—while examining prognostic factors, hospitalization risks, and mortality implications. Participants will learn when to use advanced imaging, when to screen asymptomatic patients, and how to manage coexisting conditions such as CKD, neuropathy, and autonomic dysfunction.

Future directions include metabolic modulators, gene-targeted therapy, AI-based risk modeling, and personalized exercise prescriptions. By the end, attendees will appreciate how diabetic cardiomyopathy contributes to heart failure and how proactive intervention can slow progression and improve outcomes.